Foamix (NasdaqGM: FOMX) is a clinical stage specialty pharmaceutical developing foam-based products for the treatment of a dermatological conditions. The Company’s lead product candidate FMX101 is a formulation of the approved antibiotic minocycline that is being developed for the topical treatment of moderate to severe acne vulgaris. Pivotal clinical trials in this indication are expected to begin in mid-2015. Foamix is also applying its proprietary foam technology to the treatment of other skin conditions such as impetigo, rosacea, and chemotherapy-induced rash. The Company became public through a successful IPO on September 18, 2014.